Neil H Bander MD

[Convergent Therapeutics, Inc. @ConvergentRx]

Learn more about our technology and how we are using #antibodies as a targeted therapy for delivering a #radioactive payload to #cancer cells. Check out this video below!

[Convergent Therapeutics, Inc. @ConvergentRx]

Our CEO @DrPhilKantoff, recently spoke with @GailLdutton of @biospace about our unique approach to advance #radiopharmaceutical therapy for #prostatecancer.

Read the full article here: https://t.co/f7fsII4Y42

[Phil Kantoff @DrPhilKantoff]

Great news for physicians and patients. Better staging for patients with newly diagnosed or relapsed prostate cancer @PCF_Science @DrScottTagawa @morr316 @sartor_oliver

[Phil Kantoff @DrPhilKantoff]

Excited to announce that our website has officially launched. Learn more about Convergent Therapeutics at https://t.co/o3cUr9kr9W. Developing next-generation targeted combination therapies to advance the care of cancer patients. #Cancer #Biotechnology @endpts @FierceBiotech

[Neil H Bander MD @BanderNeil]

@morr316 @morr316 appreciate the warning.

[Neil H Bander MD @BanderNeil]

@HsiehLab Very nice work. like the idea of combining with abi/enza etc.--i would think an easily testable hypothesis with your models. Any concerns about systemic effects from inhibiting translation initiation?